Mohammad-Reza Mahmoudian-Sani1,2, Ameneh Mehri-Ghahfarrokhi3, Majid Asadi-Samani4, Gholam-Reza Mobini3. 1. Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. 2. Department of Genetics and Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. 3. Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran. 4. Student Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Abstract
BACKGROUND/ OBJECTIVES: Thyroid cancer is the most common endocrine malignancy and accounts for 1% of cancers. In recent years, there has been much interest in the feasibility of using miRNAs or miRNA panels as biomarkers for the diagnosis of thyroid cancer. miRNAs are noncoding RNAs with 21-23 nucleotides that are highly conserved during evolution. They have been proposed as regulators of gene expression, apoptosis, cancer, and cell growth and differentiation. METHODS: The Directory of Open Access Journals (DOAJ), Google Scholar, PubMed (NLM), LISTA (EBSCO), and Web of Science were searched. RESULTS: The serum level of miRNAs (miRNA-375, 34a, 145b, 221, 222, 155, Let-7, 181b) can be used as molecular markers for the diagnosis and prognosis of thyroid cancer in the serum samples of patients with thyroid glands. CONCLUSIONS: Given that most common methods for the screening of thyroid cancer cannot detect the disease in its early stages, identifying miRNAs that are released in the bloodstream during the gradual progression of the disease is considered a key method in the early diagnosis of thyroid cancers.
BACKGROUND/ OBJECTIVES:Thyroid cancer is the most common endocrine malignancy and accounts for 1% of cancers. In recent years, there has been much interest in the feasibility of using miRNAs or miRNA panels as biomarkers for the diagnosis of thyroid cancer. miRNAs are noncoding RNAs with 21-23 nucleotides that are highly conserved during evolution. They have been proposed as regulators of gene expression, apoptosis, cancer, and cell growth and differentiation. METHODS: The Directory of Open Access Journals (DOAJ), Google Scholar, PubMed (NLM), LISTA (EBSCO), and Web of Science were searched. RESULTS: The serum level of miRNAs (miRNA-375, 34a, 145b, 221, 222, 155, Let-7, 181b) can be used as molecular markers for the diagnosis and prognosis of thyroid cancer in the serum samples of patients with thyroid glands. CONCLUSIONS: Given that most common methods for the screening of thyroid cancer cannot detect the disease in its early stages, identifying miRNAs that are released in the bloodstream during the gradual progression of the disease is considered a key method in the early diagnosis of thyroid cancers.
Authors: Brian D Harfe; Michael T McManus; Jennifer H Mansfield; Eran Hornstein; Clifford J Tabin Journal: Proc Natl Acad Sci U S A Date: 2005-07-22 Impact factor: 11.205
Authors: George Adrian Calin; Calin Dan Dumitru; Masayoshi Shimizu; Roberta Bichi; Simona Zupo; Evan Noch; Hansjuerg Aldler; Sashi Rattan; Michael Keating; Kanti Rai; Laura Rassenti; Thomas Kipps; Massimo Negrini; Florencia Bullrich; Carlo M Croce Journal: Proc Natl Acad Sci U S A Date: 2002-11-14 Impact factor: 11.205
Authors: Lee P Lim; Nelson C Lau; Philip Garrett-Engele; Andrew Grimson; Janell M Schelter; John Castle; David P Bartel; Peter S Linsley; Jason M Johnson Journal: Nature Date: 2005-01-30 Impact factor: 49.962
Authors: Lorenzo Moroni; Fulvio Barbaro; Florian Caiment; Orla Coleman; Sabine Costagliola; Giusy Di Conza; Lisa Elviri; Stefan Giselbrecht; Christian Krause; Carlos Mota; Marta Nazzari; Stephen R Pennington; Annette Ringwald; Monica Sandri; Simon Thomas; James Waddington; Roberto Toni Journal: Int J Mol Sci Date: 2020-05-21 Impact factor: 5.923